Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Enterprise Value (2018 - 2025)

Historic Enterprise Value for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$35.7 million.

  • Exagen's Enterprise Value fell 6201.5% to -$35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.7 million, marking a year-over-year decrease of 6201.5%. This contributed to the annual value of -$22.0 million for FY2024, which is 3961.58% up from last year.
  • Exagen's Enterprise Value amounted to -$35.7 million in Q3 2025, which was down 6201.5% from -$30.0 million recorded in Q2 2025.
  • Exagen's Enterprise Value's 5-year high stood at -$11.2 million during Q1 2025, with a 5-year trough of -$118.1 million in Q1 2021.
  • Its 5-year average for Enterprise Value is -$55.6 million, with a median of -$36.5 million in 2023.
  • Its Enterprise Value has fluctuated over the past 5 years, first crashed by 7676.61% in 2021, then skyrocketed by 5897.44% in 2025.
  • Over the past 5 years, Exagen's Enterprise Value (Quarter) stood at -$99.4 million in 2021, then surged by 37.26% to -$62.4 million in 2022, then skyrocketed by 41.51% to -$36.5 million in 2023, then soared by 39.62% to -$22.0 million in 2024, then crashed by 62.01% to -$35.7 million in 2025.
  • Its Enterprise Value stands at -$35.7 million for Q3 2025, versus -$30.0 million for Q2 2025 and -$11.2 million for Q1 2025.